Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Invested Capital (2017 - 2025)

Vistagen Therapeutics' Return on Invested Capital history spans 9 years, with the latest figure at 0.94% for Q2 2025.

  • For Q2 2025, Return on Invested Capital fell 59.0% year-over-year to 0.94%; the TTM value through Jun 2025 reached 0.94%, down 59.0%, while the annual FY2025 figure was 0.61%, N/A changed from the prior year.
  • Return on Invested Capital for Q2 2025 was 0.94% at Vistagen Therapeutics, down from 0.74% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.19% in Q1 2021 and bottomed at 0.94% in Q2 2025.
  • The 4-year median for Return on Invested Capital is 0.43% (2023), against an average of 0.5%.
  • The largest annual shift saw Return on Invested Capital tumbled -2291bps in 2021 before it surged 53bps in 2024.
  • A 4-year view of Return on Invested Capital shows it stood at 0.46% in 2021, then increased by 13bps to 0.4% in 2023, then crashed by -51bps to 0.61% in 2024, then plummeted by -55bps to 0.94% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Return on Invested Capital are 0.94% (Q2 2025), 0.74% (Q1 2025), and 0.61% (Q4 2024).